Psychotherapy Models For Patients On Ketamine Treatment In Patients With Suicidal Risk-View Presentation

Video Transcription

Video Summary

The symposium covered the therapeutic potential of ketamine in conjunction with psychotherapy, featuring experts like Dr. Jung, Dr. Altine, and Dr. Falcone. Ketamine, primarily known as an anesthetic, is being explored as a treatment for depression and suicidality due to its rapid effects. The session delved into ketamine’s dual role: as an NMDA receptor antagonist providing neuromodulation, and as a dissociative psychedelic influencing psychotherapy. Discussions emphasized the importance of psychotherapy integration, especially ketamine-assisted psychotherapy, to prolong antidepressant effects and manage trauma. Dr. Fernando S. P. Forsen shared personal insights from undergoing ketamine therapy himself, emphasizing the complementarity of psychedelic experiences and therapy. However, challenges like establishing dosing standards, potential misuse, understanding long-term effects, and insurance limitations persist.<br /><br />CAMS (Collaborative Assessment and Management of Suicidality) was highlighted as an effective intervention to reduce suicidal ideation, focusing on collaboration with the patient to navigate drivers of suicidality. The discourse recognized that while ketamine offers short-term relief of depressive symptoms, maintaining long-term benefits involving psychotherapy is crucial.<br /><br />Barriers to widespread clinical use, particularly in inpatient settings, were discussed, including regulatory hurdles and limitations in existing treatment plans to accommodate quick and efficient administration of ketamine. The symposium concluded with a call for more comprehensive research to delineate effective protocols and expanded accessibility without compromising safety, emphasizing that current practices are ahead of formal guidelines in psychedelic-assisted therapy.

Keywords

ketamine therapy

psychotherapy integration

NMDA receptor antagonist

dissociative psychedelic

antidepressant effects

trauma management

dosing standards

insurance limitations

Collaborative Assessment and Management of Suicidality

suicidal ideation

depressive symptoms

regulatory hurdles

inpatient settings

psychedelic-assisted therapy

research protocols